tris(2-carboxyethyl)phosphine | 4408-72-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tris(2-carboxyethyl)phosphine
• 英文别名: TCEP；tris-carboxyethylphosphine；Phosphino-triessigsaeure；Phosphorotriessigsaeure；(Tris(carboxymethyl)phosphine)；2-[bis(carboxymethyl)phosphanyl]acetic acid
• CAS: 4408-72-4
• 化学式: C₆H₉O₆P
• 分子量: 208.108
• InChiKey: KPTTYZMUHSMUQV-UHFFFAOYSA-N

物化性质

• 熔点：
  130 °C
• 沸点：
  504.8±45.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  bis(carboxymethyl)-dithiocarbamic acid, tripotassium salt 、 、 tris(2-carboxyethyl)phosphine 以 水 为溶剂， 生成 potassium (dithiocarbamato diacetato)aquatricarbonyl(99)technate 、 potassium (dithiocarbamato diacetato)(P(CH2COOH)3)(99)technate
  参考文献：
  名称：

  2 + 1 Chelating Systems for Binding Organometallic Fragment Tc(CO) 3 +

  摘要：

  研究了 99、99m Tc(CO) 3 + 有机金属片段与 2 + 1 螯合体系的络合。高效液相色谱分析显示，99m Tc 的二硫代氨基甲酸盐络合物比黄原酸盐、乙酰丙酮酸盐和γ-甲氧羰基甲基乙酰丙酮酸盐类似物更强。为了阻止锝配位球中的第三个空位，我们研究了硫醇、硫醚、伯胺和仲胺、羟基离子、咪唑、膦和异氰酸酯。根据 99m Tc NMR 光谱测定，混合配体配合物 Tc(CO)3(DTC)L（DTC 为二硫代氨基甲酸酯，L 为异氰酸酯、咪唑和膦类）对组氨酸挑战反应最稳定。高效液相色谱分析显示，在这些 2 + 1 系统中，只有 DTC- 异腈系统与 99m Tc(CO) 3 + 形成单一复合物。能与 99m Tc(CO) 3 + 完全结合的最小二硫代氨基甲酸-异氰酸酯浓度为 10-4 M。

  DOI：

  10.1007/s11137-005-0045-2
• 作为产物：
  描述：

  氘代3-氨基-5-吗啉-4-甲基-恶唑-2-啉酮 、 O-三甲基硅基 氯乙酸酯 生成 tris(2-carboxyethyl)phosphine
  参考文献：
  名称：

  Tzschach,A.; Friebe,S., Zeitschrift fur Chemie, 1979, vol. 19, # 10, p. 375

  摘要：

  DOI：

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE PRMT5
  申请人：ANGEX PHARMACEUTICAL INC

  公开号：WO2019112719A1

  公开（公告）日：2019-06-13

  The present disclosure describes novel PRMT5 inhibitors and methods for preparing them. The pharmaceutical compositions comprising such PRMT5 inhibitors and methods of using them for treating cancer, infectious diseases, and other PRMT5 associated disorders are also described.

  本公开描述了新型PRMT5抑制剂及其制备方法。还描述了包含这些PRMT5抑制剂的药物组合物以及将它们用于治疗癌症、传染性疾病和其他PRMT5相关疾病的方法。
• TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS
  申请人：Østergaard Henrik

  公开号：US20120093840A1

  公开（公告）日：2012-04-19

  The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human Factor VIII or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods of making and using such polypeptides.

  本发明涉及新型分子和多肽，包括至少具有与人体因子VIII或其生物活性部分显著同源性（同源性）的氨基酸序列的多肽，相关分子（如编码这些多肽的核酸），包含这些多肽的组合物（如制药配方），以及制备和使用这些多肽的方法。
• Targeted Delivery of Factor VIII Proteins to Platelets
  申请人：Novo Nordisk A/S

  公开号：US20160251409A1

  公开（公告）日：2016-09-01

  The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human Factor VIII or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods of making and using such polypeptides.

  本发明涉及一种新型分子和多肽，其中至少包含一个与人类凝血因子VIII具有重要同源性（同源性）或生物活性部分的氨基酸序列，相关分子（如编码这种多肽的核酸），包括这种多肽的组成物（如制药配方），以及制备和使用这种多肽的方法。
• A method for quantitatively determining creatine kinase and a reagent therefor
  申请人：KYOWA MEDEX CO., LTD.

  公开号：EP0774514A1

  公开（公告）日：1997-05-21

  The object of the invention is to provide a reagent for quantitatively determining creatine kinase with improved storability in liquid form as well as a method for quantitatively determining creatine kinase with stable measurements. Disclosed are a method for quantitatively determining creatine kinase, which comprises activating creatine kinase in a sample in an aqueous medium in coexistence with a trivalent phosphorus compound and a sulfhydryl-containing compound and then determining creatine kinase activity; a method for stabilizing a sulfhydryl-containing compound, which comprises allowing a trivalent phosphorus compound to coexist with a sulfhydryl-containing compound; and a reagent for quantitatively determining creatine kinase, which comprises a trivalent phosphorus compound, a sulfhydryl-containing compound, and a reaction substrate for creatine kinase.

  本发明的目的是提供一种定量测定肌酸激酶的试剂，该试剂具有更好的液态贮存性，以及一种定量测定肌酸激酶的方法，其测量结果稳定。本发明公开了一种定量测定肌酸激酶的方法，该方法包括在水介质中与三价磷化合物和含巯基化合物共存，激活样品中的肌酸激酶，然后测定肌酸激酶活性；一种稳定含巯基化合物的方法，包括使三价磷化合物与含巯基化合物共存；以及一种定量测定肌酸激酶的试剂，包括三价磷化合物、含巯基化合物和肌酸激酶的反应底物。
• METHODS AND REAGENTS FOR QUANTITATIVELY DETERMINING ASCORBIC ACID
  申请人：KYOWA MEDEX CO., LTD.

  公开号：EP0926244A1

  公开（公告）日：1999-06-30

  The present invention relates to a method for the quantitative determination of ascorbic acid in a sample using ascorbate oxidase which catalyzes the reaction of reduced form of ascorbic acid with oxygen to form oxidized ascorbic acid and hydrogen peroxide (hereinafter the enzyme is referred to as ASOD), wherein the reaction of reduced ascorbic acid with oxygen in the presence of ASOD to form oxidized ascorbic acid and hydrogen peroxide and the reaction of the formed hydrogen peroxide with a chromogen in the presence of peroxidase to form a pigment are carried out in an aqueous medium in the same reaction system, and then the formed pigment is determined. The present invention also relates to a method for the determination of total ascorbic acid, wherein the enzyme reactions are carried out in the presence of a reducing agent which is capable of converting oxidized ascorbic acid into reduced ascorbic acid in said aqueous medium. The method enables the determination of total ascorbic acid at a low concentration. The present invention further relates to a method for the determination of total ascorbic acid, wherein oxidized ascorbic acid in said sample is reduced by the use of a reducing agent which is capable of converting oxidized ascorbic acid into reduced ascorbic acid, and then the enzyme reactions are carried out in the presence of a compound which is capable of deactivating the reducing agent. Furthermore, the present invention relates to a reagent and a kit for the determination of ascorbic acid suitable for use in the above methods. The method of the present invention is a simple method for the determination of ascorbic acid which is applicable to screening in clinical assays and which is capable of analyzing a large number of samples at the same time.

  本发明涉及一种利用抗坏血酸氧化酶定量测定样品中抗坏血酸的方法，抗坏血酸氧化酶可催化还原型抗坏血酸与氧反应生成氧化型抗坏血酸和过氧化氢（以下将该酶称为 ASOD）、在同一反应体系中，还原型抗坏血酸在 ASOD 的存在下与氧反应生成氧化型抗坏血酸和过氧化氢，生成的过氧化氢在过氧化物酶的存在下与发色剂反应生成色素，然后测定生成的色素。 本发明还涉及一种测定总抗坏血酸的方法，其中酶反应是在还原剂存在下进行的，还原剂能够在所述水介质中将氧化的抗坏血酸转化为还原的抗坏血酸。该方法可以测定低浓度的总抗坏血酸。 本发明还涉及一种测定总抗坏血酸的方法，其中通过使用能够将氧化抗坏血酸转化为还原抗坏血酸的还原剂来还原所述样品中的氧化抗坏血酸，然后在能够使还原剂失活的化合物存在下进行酶反应。 此外，本发明还涉及一种适用于上述方法的测定抗坏血酸的试剂和试剂盒。 本发明的方法是一种测定抗坏血酸的简单方法，适用于临床检测中的筛选，能够同时分析大量样品。